Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 270 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: methylphenidate HCl (Concerta) Clear all
Completed Early Phase 1 Interventional

Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD

NCT02874690
View directory record Official record
Conditions
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Phase 3 Interventional

Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)

NCT00018863
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
3 Years to 5 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)

NCT01070394
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LDX Treatment
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Phase 4 Interventional

A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder

NCT00181571
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate HCl (Concerta), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 31, 2026, 7:30 AM EDT
Withdrawn No phase listed Observational

Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates

NCT00865332
View directory record Official record
Conditions
Cocaine Addiction, Cocaine Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 31, 2026, 7:30 AM EDT
Terminated Phase 3 Interventional

Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors

NCT00031798
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Depression, Fatigue, Quality of Life
Interventions
methylphenidate hydrochloride, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
7
States / cities
Phoenix, Arizona • Decatur, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 31, 2026, 7:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding Sleep Problems in Children With Autism Spectrum Disorder

NCT00691080
View directory record Official record
Conditions
Sleep Problems
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
4 Years to 9 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
3
States / cities
New York, New York • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Phase 4 Interventional Results available

Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

NCT00585910
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine and OROS Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 31, 2026, 7:30 AM EDT
Terminated Phase 3 Interventional Results available

Intervention for Teens With ADHD and Substance Use

NCT02502799
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Brief Early Intervention, Parent Training with Adolescent Cognitive Behavioral Therapy, Methylphenidate
Behavioral · Drug
Lead sponsor
Florida International University
Other
Eligibility
12 Years to 16 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

NCT02493777
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Early Phase 1 Interventional

Brain Dopaminergic Signaling in Opioid Use Disorders

NCT03190954
View directory record Official record
Conditions
Normal Physiology, Opioid Use Disorders
Interventions
[11C]raclopride plus placebo, [11C]raclopride plus drug, [11C]NNC-112
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Phase 4 Interventional Results available

Lab School Day Study for CONCERTA of Older Children With ADHD

NCT00799409
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo/ CONCERTA (methylphenidate HCl), CONCERTA (methylphenidate HCl) / Placebo
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
9 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Irvine, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 31, 2026, 7:30 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Stimulant Effects on Disruptive Behavior

NCT03420339
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Problem Behavior
Interventions
Stimulant
Drug
Lead sponsor
Matthew J O'Brien, PhD, BCBA-D
Other
Eligibility
48 Months to 12 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Phase 4 Interventional Results available

Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist

NCT01673594
View directory record Official record
Conditions
ADHD, Stimulant-Induced Euphoria
Interventions
SODAS MPH, Naltrexone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 30 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 31, 2026, 7:30 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

NCT03525873
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Laboratory Biomarker Analysis, Methylphenidate, Physical Activity, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 7:30 AM EDT
Suspended Phase 3 Interventional

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

NCT05924594
View directory record Official record
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
Interventions
CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 31, 2026, 7:30 AM EDT
Not listed Phase 2 Interventional

The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome

NCT01966276
View directory record Official record
Conditions
Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME)
Interventions
Methyl-P plus Nutrient Formula, Methyl-P plus Nutrient matched placebos
Drug
Lead sponsor
K-PAX Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Stanford, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects

NCT04449250
View directory record Official record
Conditions
Healthy Volunteers in Fed and Fasted State
Interventions
Dexmethylphenidate
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

NCT01993108
View directory record Official record
Conditions
Healthy, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Naltrexone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label, Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation

NCT01290276
View directory record Official record
Conditions
Healthy
Interventions
Ond-PR1, Ond-PR1 + MPh-IR, Ond-PR2, Ond-PR2 +_ MPh-IR
Drug
Lead sponsor
Tong Lee
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Not applicable Interventional

Sleep/Wake State Assessment with Non-invasive Earbuds

NCT05066009
View directory record Official record
Conditions
Hypersomnolence
Interventions
NextSense EEG-enabled earbuds, Ellcie Healthy eyeglasses, Drug Holiday
Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 31, 2026, 7:30 AM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)

NCT01377662
View directory record Official record
Conditions
Methamphetamine Dependence, Cocaine Dependence
Interventions
OND-PR002 and MPh-IR, Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR
Drug · Other
Lead sponsor
Tong Lee
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 31, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)

NCT00603434
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse
Interventions
OROS-MPH
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 31, 2026, 7:30 AM EDT